ok so i saw in the investor presentation a $100m ARR target value by cy2021... it could go something like this... assume $13.3m pa organic growth between now and 2021 (low considering history) with an annual acquisition netting a further $10m pa puts them at $100m ARR and with an 10x multiplier that's $1bn value. hoping the focus to improve operating cash flow will help the multiplier more. Assume dilution of 50m shares per acquisition taking the ~660m to 810m and a $1bn valuation makes the shares worth $1.23. I have no idea on the acquisition strategy, I'd actually assume higher balance of organic ARR growth so pls DYOR.
- Forums
- ASX - By Stock
- LVT
- Ann: Successful completion of capital raise
Ann: Successful completion of capital raise, page-41
Featured News
Add LVT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online